SynCore Biotechnology (4192:TT)

Executive Summary

SynCore Biotechnology is a Taiwan-based public biopharmaceutical company founded in 2008, specializing in novel small-molecule and biologic therapeutics for oncology, ophthalmology, and dermatology. Leveraging anti-angiogenesis and targeted drug platforms, the company has advanced a pipeline that includes Phase 3 trials for pancreatic cancer and triple-negative breast cancer, addressing significant unmet medical needs. Additionally, SynCore is developing ophthalmic diagnostics to complement its therapeutic portfolio. With a focus on innovative mechanisms and a late-stage clinical pipeline, the company is positioned to deliver potential near-term value catalysts. However, as a public company with a market presence primarily in Taiwan, SynCore faces typical biotech risks, including clinical trial outcomes and regulatory hurdles. The company's ability to execute on its pivotal studies will be critical for its growth trajectory and investor confidence.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Data Readout for Pancreatic Cancer (SP-01)60% success
• Q1 2027Phase 3 Data Readout for Triple-Negative Breast Cancer (SP-02)55% success